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In studying the epidemiology of parvovirus 4 (PARV4) 
in Taiwan, we detected DNA in plasma of 3 mothers and 
their newborns with hydrops. In 1 additional case, only the 
mother had PARV4 DNA. Our ﬁ   ndings demonstrate that 
PARV4 can be transmitted through the placenta.
T
ransmission routes of human parvovirus 4 (PARV4), 
a recently discovered member of the Parvoviridae 
family (1), are not fully understood; studies have suggested 
that PARV4 is transmitted predominantly through the 
parenteral route (2,3). To study the epidemiology of 
PARV4 infection in Taiwan, we developed an in-house 
PARV4 immunoblot (4). During the process, we found 
regions of higher similarity in amino acid sequence 
between PARV4 and parvovirus B19 virus (B19V). 
They are LPGTNYVGPGNEL (B19V VP1, aa 125–137) 
LPGYNYVGPGNPL (PARV4 open reading frame [ORF] 
2, aa 219–231) and YKYPYVLGQGQDTL (B19V VP2, 
aa 157–170) YDYPYVLGHNQDTL (PARV4 ORF2, aa 
499–512).
To exclude the possibility of antibody cross-reaction 
between PARV4 and B19V, we tested plasma samples 
sent to our laboratory for conﬁ  rmation of B19V infection 
with PARV4 immunoblot. Unexpectedly, we detected 
PARV4 DNA in plasma from a mother and her newborn 
with hydrops. Therefore, we examined samples from 5 
additional infants with hydrops.
The Study
During 2000–2009, our laboratory received blood 
samples from 6 infants with nonimmune idiopathic hydrops 
(Table 1). Paired mother–newborn plasma samples from 4 
infants were available for this study; plasma from either 
the mother or newborn was missing in 2 instances. None 
of the blood samples from the newborns was cord blood. 
All infants (case-patients) had at least 2 of the following 
conditions: ascites, pleural effusion, pericardial effusion, 
skin edema, or polyhydramnios.
Antibodies to PARV4 and B19V were tested by 
immunoblots. DNA of PARV4 and B19V was detected 
by seminested and nested PCR, respectively. PARV4 
immunoblot and PCR were performed according to the 
methods in our previous report (4). The B19V immunoblot 
and PCR are described in the online Technical Appendix 
(www.cdc.gov/EID/content/17/10/10-1841-Techapp.
pdf). The 2 fragments of the PARV4 capsid protein, aa 
272–630 and aa 604–914 of ORF2, were fused to bacterial 
small ubiquitin-like modiﬁ  er (SUMO) protein (a member 
of a ubiquitin-like protein family) and used as antigens in 
immunoblot. They were named viral protein (VP) 2 and 
VP3. For B19V, the antigens were VP1-speciﬁ  c (VP1-S; 
VP1, aa 1–227) fused to thioredoxin and VP2N (N 
terminal of B19V VP2, aa 1–343) fused to SUMO. The 
control protein was ribosomal P2 protein fused to SUMO. 
Antibodies to ribosomal P2 protein were rarely detected, 
except in patients with systemic lupus erythematosus (5).
Four of the 5 mothers had immunoglobulin (Ig) M 
against PARV4 (Table 2). Two of the 4 also had IgG 
against PARV4 (Figure, A, E); the other 2 had weakly 
positive IgM without IgG (not shown). No newborn had 
IgM against PARV4. We detected IgM against B19V 
in only 1 mother (Figure, A), who also had IgM against 
PARV4. None of the newborns had IgM against B19V. 
Two mothers (Figure, B, E) and 2 newborns had IgG 
against VP2N but not VP1S. The immunoblot pattern 
of IgG against B19V was inconsistent with ﬁ  ndings in a 
previous report (6).
Only the mother and newborn of case A had detectable 
B19V DNA (genotype 1). By contrast, PARV4 DNA 
(genotype 2) was found in plasma of all but 1 of the 6 case-
patients. The newborn negative for PARV4 DNA received 
a whole-blood exchange before sampling.
Conclusions
The ﬁ  rst serologic study (7) and a recent study (8), 
both conducted in northern Europe, supported the fact 
that PARV4 is primarily a blood-borne virus. PARV4 
DNA was detected in blood donors (9,10), and detection 
rates were 2% and 3.95%, respectively. The PARV4 
seropositivity rate is expected to be higher than the DNA 
detection rate in blood donors because of the possibility of 
past infection (2,11,12). However, the IgG seroprevalence 
in 199 blood donors in France was 0%; the same rate was 
found in the general population in the United Kingdom 
(13). A much lower PARV4 DNA detection rate in blood 
donors in France may explain the result. Inconsistent with 
the  ﬁ  ndings of extremely low seroprevalence in France 
and the United Kingdom, PARV4 DNA was detected in 
the liver (15% and 41%, respectively) and the heart (41%) 
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of non–HIV-infected patients in Germany (11) and Italy 
(14). PARV4 infection might be more widespread in some 
countries in Europe.
Contrary to the epidemiology of PARV4 in Europe, 
studies in Africa found different transmission routes and 
a higher seropositive rate in blood donors and the general 
population. In Ghana, 8.6% of infants had PARV4 viremia 
(15). In sub-Saharan Africa, 20%–37% of adults studied 
had antibodies to PARV4 (13). The groups studied in both 
reports did not have parenteral risk.
PARV4 can be transmitted through nonparenteral 
routes (13,15). Our study showed that placental 
transmission is one of them. PARV4 was unlikely to have 
been transmitted through a blood transfusion because of the 
low detection rate of PARV4 DNA in the blood donors. 
Because Taiwan has a high PARV4 seroprevalence rate 
(4), the possibility of a higher PARV4 DNA detection rate 
in blood donors is of concern. However, considering that 
the PARV4 seropositivity rate was 76.8% in HIV-infected 
intravenous drug users but only 6 of 350 had detectable 
DNA (4), the concern is not realistic.
Maternal PARV4 infections were diagnosed by 
detection of PARV4 DNA in all 5 mothers; 4 of whom 
had IgM against PARV4. Using IgM against PARV4 as 
evidence of recent infection must be done cautiously 
because of persistent IgM against PARV4 (4). Two 
mothers had weak IgM but no IgG against PARV4. The 
possibility of nonspeciﬁ  c IgM binding is low because of 
PARV4 viremia. The IgM result may be negative if the 2 
samples are tested by enzyme immunoassay. The 2 mothers 
might have defective humoral immunity against PARV4 
because we had detected 4 non–HIV-infected patients who 
had persistent IgM against PARV4 but did not have (or had 
weakly positive) IgG against PARV4 over 9–35 months. 
In a mother without IgM against PARV4, the amount of 
IgM might rapidly decline or a relapse of viremia might 
occur. In our previous longitudinal study of blood with IgM 
against PARV4, we found PARV4 DNA transiently during 
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Table 1. Clinical information about 6 infants with hydrops, Taiwan, 2000–2009* 
Patient Sex Delivery 
Gestational 
age, wk 
Birthweight, 
g Hydrops  signs 
Hemoglobin, 
g/dL Transfusion† 
Platelets, 
10
3/ȝL Outcome 
A F  CS 35 2,846  Pericardial  effusion, 
polyhydramnios 
8.1 Yes  NA  Survived 
B  M  Vaginal  40  2,468  Pleural effusion, skin 
edema 
7.9 Yes  183  Survived 
C F  CS 32 3,070  Pleural  effusion,  skin 
edema 
7.8 Yes  22  Died 
D M  CS 35 3,030  Ascites,  pericardial 
effusion 
4.1 Yes 6  Survived 
E  M  Vaginal  27  1,450  Pleural effusion, skin 
edema 
13 No  232  Survived 
F M  CS 32 2,634  Ascites,  pleural 
effusion 
12 No  76  Died 
*CS, cesarean section; NA, not available. 
†All transfusions were given after delivery. Blood samples were collected on the second (patients A–D) or third (E, F) day after delivery. 
 
Table 2. Antibody to B19V and PARV4 and detection of viral DNA in mothers and newborns, Taiwan, 2000–2009* 
Case and patient 
B19V PARV4
Antibody DNA Antibody  DNA
A
  Mother  IgM+, IgG+; anti-VP1 and 2  + IgM+, IgG+  +
  Newborn  IgM–, IgG+; anti-VP1 and 2  + IgM–, IgG+  +
B
  Mother  IgM–, IgG+ to VP2 only  – IgM–, IgG+  +
  Newborn  IgM–, IgG+; to VP2 only  – IgM–, IgG+  +
C
  Mother  IgM–, IgG–  – IgM weak +, IgG–  +
  Newborn  IgM–, IgG–  – IgM–, IgG–  –
D
  Mother  IgM–, IgG–  – IgM weakly positive, IgG–  +
  Newborn  IgM–, IgG–  – IgM–, IgG–  +
E
  Mother  IgM weakly positive, IgG+, to VP2 only  – IgM+, IgG+  +
F
  Newborn  IgM–, IgG+; to VP2 only  – IgM–, IgG+  +
*B19V, parvovirus B19 virus; PARV4, parvovirus 4; Ig, immunoglobulin; +, positive; VP, viral protein; –, negative. follow-up in 1 case (4). The mother without IgM against 
PARV4 was pregnant again 2 years later, and fetal death 
occurred at 18 weeks’ gestation.
Persons with past B19V infection are expected to have 
IgG against B19V VP1 but not VP2 in immunoblot (6). 
On the contrary, 4 samples in this study had IgG against 
VP2N but not VP1S. We excluded the possibility of a 
reaction with SUMO protein by testing with the control 
protein. We tested 32 samples that had IgG against PARV4 
and B19V VP2N using a commercial IgG B19V enzyme 
immunoassay (IBL, Hamburg Germany); 9 tested positive 
by IBL, and 8 were deﬁ  nitely positive because IgG against 
VP2N and VP1S were positive in our B19V immunoblot. 
Twenty-four samples had IgG against VP2N but not VP1S, 
only one of which tested positive by IBL. The paradoxical 
result was not seen in 47 blood samples without IgG against 
PARV4. Therefore, the best explanation is that PARV4 
antibodies can cross-react with those of B19V VP2N.
In conclusion, PARV4 can be transmitted parenterally 
and placentally. Other transmission routes might exist and 
remain to be discovered. Prospective studies of PARV4 
infection during pregnancy are needed to clarify the effect 
of PARV4 infection on fetal outcome.
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Figure. Immunoglobulin (Ig) G and IgM immunoblots of 3 mothers 
for infection with parvovirus 4 (PARV4) (left) or parvovirus B19 
(B19V) (right). Case-patient A was co-infected with PARV4 and 
B19V; case-patient B was the only mother who did not have IgM 
against PARV4; case-patient E had weak IgM against PARV4 viral 
protein (VP) 3 and IgM against B19V VP2N, which could not be 
seen after scanning. Molecular weights are ≈60 kDa for PARV4 
VP2, 51 kDa for PARV4 VP3, 51 kDa for B19V VP2N, and 41 kDa 
for B19V VP1S.